<DOC>
	<DOCNO>NCT00444028</DOCNO>
	<brief_summary>Staccato Loxapine develop treatment acute agitation patient schizophrenia . A 50 patient , dose escalation Phase I clinical trial complete November 2005 .</brief_summary>
	<brief_title>Staccato® Loxapine Inhalation Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<criteria>1 . Male female subject age 18 55 year , inclusive . 2 . Subjects body mass index ( BMI ) ≥21 ≤30 . 3 . Subjects speak , read , understand English willing able provide write informed consent IRBapproved form prior initiation study procedure . 4 . Subjects willing able confine Clinical Research Unit ( CRU ) approximately 2 day comply study schedule study requirement . 5 . Subjects good general health determine complete medical history , physical examination , 12lead ECG , spirometry , blood chemistry profile , hematology , urinalysis . 1 . Subjects regularly consume large amount xanthinecontaining substance ( i.e. , 5 cup coffee equivalent amount xanthinecontaining substance per day ) . 2 . Subjects take prescription nonprescription medication ( exception vitamin acetaminophen medically necessary ) within 5 day Visit 2 ( Baseline ) . 3 . Subjects acute illness within 5 day Visit 2 ( Baseline ) . 4 . Subjects receive investigational drug within 30 day ( within 5 half life investigational drug , &gt; 30 day ) prior Visit 2 ( Baseline ) . 5 . Subjects smoke tobacco within last year . 6 . Subjects history within past 2 year drug alcohol dependence abuse define DSM4 . 7 . Subjects history HIV positivity . 8 . Subjects history allergy intolerance dibenzoxazepines ( amoxapine loxapine ) . 9 . Subjects know history contraindication anticholinergic ( bowel obstruction , urinary retention , acute glaucoma ) . 10 . Subjects history pheochromocytoma , seizure disorder , Parkinson ’ disease , Restless Leg Syndrome ( RLS ) . 11 . Subjects test positive alcohol positive urine drug screen Visit 1 Visit 2 . 12 . Subjects hypotension ( systolic blood pressure ≤90 mmHg , diastolic blood pressure ≤50 mmHg ) , hypertension ( systolic blood pressure ≥140 mmHg , diastolic blood pressure ≥90 mmHg ) . 13 . Subjects clinically significant ECG abnormality . 14 . Subjects history unstable angina , syncope , coronary artery disease , myocardial infarction , congestive heart failure ( CHF ) , stroke , transient ischemic attack ( TIA ) , neurological disorder . 15 . Subjects history pulmonary disease precludes administration Staccato Loxapine ( asthma , bronchitis , bronchospasm , emphysema ) . 16 . Subjects FEV1 le 80 % predict value spirometry assessment Visit 1 . 17 . Female subject breastfeed positive pregnancy test Visit 1 Visit 2 . 18 . Female participant childbearing potential within 1 year menopause , sexually active exclude unless use medically acceptable effective birth control method throughout study 1 week follow end study . Medically acceptable method contraception include abstinence , diaphragm spermicide , intrauterine device ( IUD ) , condom foam spermicide , vaginal spermicidal suppository , surgical sterilization , birth control pill . Unacceptable method include : rhythm method , withdrawal , condoms alone , diaphragm alone . 19 . Subjects disease condition , history , physical examination , laboratory abnormality investigator ’ opinion , would present undue risk subject , may confound interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Schizophrenia , Staccato Loxapine</keyword>
</DOC>